LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.07 -5.63

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.05

Massimo

13.83

Metriche Chiave

By Trading Economics

Entrata

-6.9M

6M

Vendite

9.4M

162M

P/E

Media del settore

69.6

56.602

Margine di Profitto

3.676

Dipendenti

1,811

EBITDA

5.6M

-5M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+11.87% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-183M

2.5B

Apertura precedente

18.7

Chiusura precedente

13.07

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2025, 23:20 UTC

Utili

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mag 2025, 23:48 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mag 2025, 23:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mag 2025, 23:24 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

13 mag 2025, 23:24 UTC

Discorsi di Mercato
Utili

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mag 2025, 22:58 UTC

Utili

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mag 2025, 22:38 UTC

Utili

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mag 2025, 22:38 UTC

Utili

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mag 2025, 22:37 UTC

Utili

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mag 2025, 22:36 UTC

Utili

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mag 2025, 22:35 UTC

Utili

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mag 2025, 22:34 UTC

Utili

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mag 2025, 22:30 UTC

Utili

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mag 2025, 22:30 UTC

Utili

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mag 2025, 22:29 UTC

Utili

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mag 2025, 22:28 UTC

Utili

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mag 2025, 21:15 UTC

Utili

Nu Holdings 1Q Rev $3.2B >NU

13 mag 2025, 21:03 UTC

Notizie principali

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

13 mag 2025, 20:32 UTC

Utili

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mag 2025, 20:31 UTC

Utili

Alcon 1Q Sales $2.45B >ALC.EB

13 mag 2025, 20:30 UTC

Utili

Alcon 1Q Rev $2.47B >ALC.EB

13 mag 2025, 20:30 UTC

Utili

Alcon 1Q EPS 70c >ALC.EB

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

11.87% in crescita

Previsioni per 12 mesi

Media 14.7 USD  11.87%

Alto 14.7 USD

Basso 14.7 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.